Esperion Drug Patent Portfolio
Esperion owns 2 orange book drugs protected by 13 US patents Given below is the list of Esperion's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11613511 | Methods of making bempedoic acid and compositions of the same | 19 Jun, 2040 | Active |
| US11760714 | Methods of making bempedoic acid and compositions of the same | 19 Jun, 2040 | Active |
| US11926584 | Methods of making bempedoic acid and compositions of the same | 19 Jun, 2040 | Active |
| US12398087 | Methods Of Making Bempedoic Acid And Compositions Of The Same | 19 Jun, 2040 | Active |
| US12404227 | Methods Of Making Bempedoic Acid And Compositions Of The Same | 19 Jun, 2040 | Active |
| US11744816 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | 14 Mar, 2036 | Active |
| US10912751 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | 14 Mar, 2036 | Active |
| US7335799 | Hydroxyl compounds and compositions for cholesterol management and related uses | 03 Dec, 2030 | Active |
| US10118881 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US10941095 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US8497301 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US9000041 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
| US9624152 | Hydroxyl compounds and compositions for cholesterol management and related uses | 23 Dec, 2023 | Expired |
Latest Legal Activities on Esperion's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Esperion.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 09 Sep, 2025 | US12404227 |
| Recordation of Patent Grant Mailed | 09 Sep, 2025 | US12404227 |
| Patent Issue Date Used in PTA Calculation | 02 Sep, 2025 | US12404227 |
| Recordation of Patent eGrant | 02 Sep, 2025 | US12404227 |
| Email Notification | 02 Sep, 2025 | US12404227 |
| Patent eGrant Notification | 02 Sep, 2025 | US12404227 |
| Patent eGrant Notification | 02 Sep, 2025 | US12404227 |
| Patent Issue Date Used in PTA Calculation | 02 Sep, 2025 | US12404227 |
| Mail Patent eGrant Notification | 02 Sep, 2025 | US12404227 |
| Recordation of Patent eGrant | 02 Sep, 2025 | US12404227 |
| Recordation of Patent Grant Mailed | 02 Sep, 2025 | US12398087 |
| Email Notification | 02 Sep, 2025 | US12404227 |
| Recordation of Patent Grant Mailed | 02 Sep, 2025 | US12398087 |
| Mail Patent eGrant Notification | 02 Sep, 2025 | US12404227 |
| Expire Patent | 01 Sep, 2025 | US8497301 |
Esperion's Family Patents
Esperion drugs have patent protection in a total of 24 countries. It's US patent count contributes only to 40.6% of its total global patent coverage. Click
below to unlock the full patent family tree.
Esperion Drug List
Given below is the complete list of Esperion's drugs and the patents protecting them.
1. Nexletol
Nexletol is protected by 12 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11613511 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(14 years from now)
| Active |
| US11760714 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(14 years from now)
| Active |
| US11926584 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(14 years from now)
| Active |
| US12398087 | Methods Of Making Bempedoic Acid And Compositions Of The Same |
19 Jun, 2040
(14 years from now)
| Active |
| US12404227 | Methods Of Making Bempedoic Acid And Compositions Of The Same |
19 Jun, 2040
(14 years from now)
| Active |
| US11744816 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
14 Mar, 2036
(9 years from now)
| Active |
| US7335799 | Hydroxyl compounds and compositions for cholesterol management and related uses |
03 Dec, 2030
(4 years from now)
| Active |
| US10118881 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US10941095 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US8497301 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US9000041 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US9624152 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexletol's drug page
2. Nexlizet
Nexlizet is protected by 13 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11613511 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(14 years from now)
| Active |
| US11760714 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(14 years from now)
| Active |
| US11926584 | Methods of making bempedoic acid and compositions of the same |
19 Jun, 2040
(14 years from now)
| Active |
| US12398087 | Methods Of Making Bempedoic Acid And Compositions Of The Same |
19 Jun, 2040
(14 years from now)
| Active |
| US12404227 | Methods Of Making Bempedoic Acid And Compositions Of The Same |
19 Jun, 2040
(14 years from now)
| Active |
| US10912751 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
14 Mar, 2036
(9 years from now)
| Active |
| US11744816 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
14 Mar, 2036
(9 years from now)
| Active |
| US7335799 | Hydroxyl compounds and compositions for cholesterol management and related uses |
03 Dec, 2030
(4 years from now)
| Active |
| US10118881 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US10941095 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US8497301 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US9000041 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
| US9624152 | Hydroxyl compounds and compositions for cholesterol management and related uses |
23 Dec, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexlizet's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List